Brief: Ascletis Announces Results Of Subcutaneous Depot Maintenance Formulation Of Small Molecule GLP-1R Agonist ASC30 Testing
09/09/2025 11:41
Sept 9 (Reuters) - Ascletis Pharma Inc 1672.HK: ASCLETIS ANNOUNCES ULTRA-LONG-ACTING SUBCUTANEOUS DEPOT MAINTENANCE FORMULATION OF SMALL MOLECULE GLP-1R AGONIST ASC30 DEMONSTRATED AN OBSERVED HALF-LIFE OF 75 DAYS IN PARTICIPANTS WITH OBESITY Source text: ID:nPn7l4SjKa Further company coverage: 1672.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026